A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study

Y. M. Chiu, C. H. Tang, S. T. Hung, Y. W. Yang, C. H. Fang, H. Y. Lin

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science